Attached files

file filename
EX-5.1 - LEGAL OPINION - Axium Pharmaceuticals Inc.axium_s1a-ex0501.htm
S-1/A - FORM S-1 AMENDMENT - Axium Pharmaceuticals Inc.axium_s1a4.htm

Exhibit 23.2


Weinberg & Baer LLC

115 Sudbrook Lane, Baltimore, MD 21208

Phone (410) 702-5660



Mr. Anthony Harrelson, CEO

Axium Pharmaceuticals Inc.

265 Eastchester Drive, Suite 133

High Point, NC 27262 


Dear Mr. Harrelson:




We have issued our report dated July 27, 2017, with respect to the June 30, 2017 financial statements of Axium Pharmaceuticals Inc. contained in the Registration Statement and Prospectus of Axium Pharmaceuticals Inc. on amended Form S-1. We hereby consent to the use of the aforementioned report in the Registration Statement and Prospectus, and to the use of our name as it appears under the heading “Experts.”


Respectfully submitted,




Weinberg & Baer LLC

Baltimore, Maryland

November 9, 2017